

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WUXI APPTEC CO., LTD.\***  
**無錫藥明康德新藥開發股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2359)**

**VOLUNTARY ANNOUNCEMENT**

This announcement is made by WuXi AppTec Co., Ltd.\* (無錫藥明康德新藥開發股份有限公司) (the “**Company**” or “**WuXi AppTec**”) on a voluntary basis.

Reference is made to the announcements of the Company dated January 26, 2024, January 29, 2024 and February 4, 2024, in relation to, among other things, WuXi AppTec being named in certain proposed legislation that was recently introduced to the U.S. House of Representatives and the U.S. Senate.

The Company hereby clarifies that our company name is “WuXi AppTec Co., Ltd.”. Wuxi or WuXi is not our company’s name but the pinyin name of the city “無錫”, which is located in the Yangtze River Delta in eastern China, approximately 80 miles from Shanghai. We are a foreign-invested joint stock company incorporated in the city of Wuxi, where we started our Contract Research Organization (CRO) business over two decades ago.

The Company also reiterates that we do not have a human genomics business and we do not collect human genomic data in our businesses. We provide contract-based research, development and manufacturing services that enable the global pharmaceutical and life sciences industries to advance discoveries and deliver lifesaving drugs to patients.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board  
**WuXi AppTec Co., Ltd.\***  
**Dr. Ge Li**  
*Chairman*

Hong Kong, February 13, 2024

*As of the date of this announcement, the board of directors of the Company comprises Dr. Ge Li, Dr. Minzhang Chen, Mr. Edward Hu, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Dai Feng as independent non-executive Directors.*

\* For identification purposes only